Recently Viewed
Clear All$0.86
$-0.09
(-9.19%)
As on 02-Apr-2026 15:59EDT
Today’s Range
52 Week Range
Liquidity
Market cap
$10 Mln
Revenue (TTM)
$1 Mln
Net Profit (TTM)
$0 Mln
ROE
-11.2 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
54.5
Industry P/E
--
EV/EBITDA
-1.7
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-1.5
Face value
--
Shares outstanding
11,034,775
CFO
$-144.99 Mln
EBITDA
$-162.30 Mln
Net Profit
$-162.24 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Brainstorm Cell Therapeutics (BCLI)
| 56.0 | 23.3 | 56.0 | -27.5 | -74.1 | -56.8 | -32.1 |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Brainstorm Cell Therapeutics (BCLI)
| -75.6 | -44.3 | -83.4 | -59.0 | -11.6 | 5.7 | 20.6 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Brainstorm Cell Therapeutics (BCLI)
|
0.9 | 9.6 | 0.9 | -10.9 | -1,283.6 | -- | -- | 54.5 |
| 61.0 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 229.3 | 13,405.2 | 691.7 | -219.0 | -13.7 | 163.2 | -- | 14.6 | |
| 66.7 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 43.9 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 93.8 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 546.9 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 498.3 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 105.4 | 7,603.8 | 0.0 | -425.4 | -- | -36.7 | -- | 6.0 | |
| 310.4 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Brainstorm Cell Therapeutics Inc. a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company's NurOwn proprietary cell therapy platform that... leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is involved in the development of NurOwn, which has completed Phase IIIb clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for treatment of other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York. Address: 1325 Avenue of Americas, New York, NY, United States, 10019 Read more
President & Co-CEO
Mr. Chaim Lebovits
President & Co-CEO
Mr. Chaim Lebovits
Headquarters
New York, NY
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Brainstorm Cell Therapeutics Inc (BCLI) is $0.86 (NASDAQ) as of 02-Apr-2026 15:59 EDT. Brainstorm Cell Therapeutics Inc (BCLI) has given a return of -74.08% in the last 3 years.
Since, TTM earnings of Brainstorm Cell Therapeutics Inc (BCLI) is negative, P/E ratio is not available.
The P/B ratio of Brainstorm Cell Therapeutics Inc (BCLI) is 54.50 times as on 31-Mar-2026, a 1283 premium to its peers’ median range of 3.94 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
1.11
|
-1.67
|
|
2023
|
-0.05
|
-0.17
|
|
2022
|
-0.17
|
-1.33
|
|
2021
|
-0.40
|
0.50
|
|
2020
|
-0.30
|
0.27
|
The 52-week high and low of Brainstorm Cell Therapeutics Inc (BCLI) are Rs 1.92 and Rs 0.46 as of 04-Apr-2026.
Brainstorm Cell Therapeutics Inc (BCLI) has a market capitalisation of $ 10 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Brainstorm Cell Therapeutics Inc (BCLI), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.